- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.04. | Protagenic ernennt Bill Nichols zum Präsidenten, Finanzvorstand tritt zurück | 2 | Investing.com Deutsch | ||
| 23.04. | Protagenic Therapeutics, Inc.: Protagenic Therapeutics Appoints Industry Veteran Bill Nichols Jr. as President to Accelerate Advancement of First-in-Class TCAP Pathway Therapy PT00114 | 254 | ACCESS Newswire | NEW YORK, NY / ACCESS Newswire / April 23, 2026 / Protagenic Therapeutics, Inc. (OTCQB:PTIX), a clinical-stage biopharmaceutical company pioneering first-in-class neuropeptide therapies for stress-related... ► Artikel lesen | |
| 07.04. | Protagenic Therapeutics, Inc.\new - 8-K, Current Report | - | SEC Filings | ||
| 17.03. | Protagenic settles Phytanix separation, cuts liabilities by $6.3M | 2 | Investing.com | ||
| 17.03. | Protagenic Therapeutics, Inc.: Protagenic Therapeutics Completes Phytanix Separation, Strengthens Balance Sheet and Repositions the Company Around PT00114 | 230 | ACCESS Newswire | Returned and cancelled merger shares, removal of more than $6.3 million of liabilities and over $1 million of annualized cost savings position Protagenic as a leaner company centered on PT00114 NEW... ► Artikel lesen | |
| 10.03. | Protagenic Therapeutics, Inc.: Protagenic Therapeutics Upgrades from OTC Pink to OTCQB Venture Market | 210 | ACCESS Newswire | Move strengthens market visibility, supports liquidity and real-time quote access as PT00114 advances toward Phase 2 in 2026 NEW YORK CITY, NY / ACCESS Newswire / March 10, 2026 / Protagenic Therapeutics... ► Artikel lesen | |
| PROTAGENIC THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 09.03. | Protagenic Therapeutics, Inc.\new - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 03.03. | Protagenic Therapeutics beruft William Nichols Jr. zum President | 2 | Investing.com Deutsch | ||
| 03.03. | Protagenic Therapeutics, Inc.\new - 8-K, Current Report | - | SEC Filings | ||
| 24.02. | Protagenic Therapeutics, Inc.\new - 8-K, Current Report | - | SEC Filings | ||
| 18.02. | Protagenic Therapeutics, Inc.\new - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | 2 | SEC Filings | ||
| 23.01. | NSE - Protagenic Therapeutics, Inc.\new - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | 2 | SEC Filings | ||
| 05.01. | Protagenic Therapeutics wechselt nach NASDAQ-Delisting in den OTC-Handel | 6 | Investing.com Deutsch | ||
| 05.01. | Protagenic Therapeutics, Inc.\new - 8-K, Current Report | 1 | SEC Filings | ||
| 09.12.25 | Protagenic Therapeutics, Inc.: Results from Phase 1 Multiple-Dose Study of PT00114 | 425 | ACCESS Newswire | Findings support advancement into Phase 2 to explore a first-in-class pathway aimed at stress-related neuropsychiatric conditions NEW YORK CITY, NEW YORK / ACCESS Newswire / December 9, 2025 / Protagenic... ► Artikel lesen | |
| 27.11.25 | Protagenic Therapeutics receives Nasdaq non-compliance letter | 5 | Seeking Alpha | ||
| 27.11.25 | Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice | 589 | ACCESS Newswire | NEW YORK, NY / ACCESS Newswire / November 27, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) (the "Company") today announced that it has received a notification letter from the Nasdaq Listing Qualifications... ► Artikel lesen | |
| 26.11.25 | Protagenic Therapeutics, Inc.\new - 10-Q, Quarterly Report | - | SEC Filings | ||
| 26.11.25 | Protagenic Therapeutics, Inc.\new - 8-K, Current Report | - | SEC Filings | ||
| 13.11.25 | Protagenic Therapeutics, Inc.: Protagenic Therapeutics Announces Completion of Enrollment and Dosing in Phase 1 MAD Study | 334 | ACCESS Newswire | NEW YORK CITY, NY / ACCESS Newswire / November 13, 2025 / Protagenic Therapeutics Inc. (NASDAQ:PTIX), a biopharmaceutical company developing novel therapeutics for stress-related neuropsychiatric and... ► Artikel lesen |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDIGENE | 0,036 | -9,50 % | MEDIGENE AG - Schwäche mit Signalcharakter | ||
| VALNEVA | 2,540 | -0,51 % | Valneva senkt Prognose und baut Stellen ab | Beim Impfstoffspezialisten Valneva SE häufen sich im ersten Quartal 2026 die Belastungen: Der Nettoverlust weitete sich auf 32,1 Millionen Euro nach 9,2 Millionen Euro im Vorjahr aus, das bereinigte... ► Artikel lesen | |
| BIOFRONTERA | 2,270 | -3,81 % | PTA-HV: Biofrontera AG: Einladung zur ordentlichen Hauptversammlung | DJ PTA-HV: Biofrontera AG: Einladung zur ordentlichen Hauptversammlung
Hauptversammlung gemäß -- 121 Abs. 4a AktG
Biofrontera AG: Einladung zur ordentlichen Hauptversammlung
Leverkusen... ► Artikel lesen | |
| 4SC | 0,100 | -23,37 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 16.12.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 16.12.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 16.12.2025ISIN NameDE000A3E5C40 4SC... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 19,000 | +13,98 % | PALATIN TECHNOLOGIES INC - 10-Q, Quarterly Report | ||
| INOVIO PHARMACEUTICALS | 1,119 | -3,28 % | Full Transcript: Inovio Pharmaceuticals Q1 2026 Earnings Call | ||
| SANGAMO THERAPEUTICS | 0,126 | 0,00 % | XFRA GBY: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILSANGAMO THERAP.INC.DL-... ► Artikel lesen | |
| VIKING THERAPEUTICS | 26,950 | -0,55 % | Viking Therapeutics, Inc.: Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | Conference call scheduled for 4:30 p.m. ET today
-- Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Advance; VANQUISH-1 and VANQUISH-2 Trials Fully Enrolled... ► Artikel lesen | |
| SIRONA BIOCHEM | 0,037 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 24.04.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 24.04.2026.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 24.04.2026.ISIN NameCA46658Y1034 J2... ► Artikel lesen | |
| EDITAS MEDICINE | 2,480 | 0,00 % | Editas Medicine, Inc.: Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference | CAMBRIDGE, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today... ► Artikel lesen | |
| VAXART | 0,380 | 0,00 % | Vaxart anticipates early 2027 primary efficacy readout while aiming for Q2 sentinel data release | ||
| IMMUNITYBIO | 7,080 | +1,72 % | ImmunityBio Stock Drops After Earnings Miss Despite Anktiva Momentum | ||
| MICROBOT MEDICAL | 1,905 | +2,42 % | Microbot Medical Inc. - 10-Q, Quarterly Report | ||
| RECURSION PHARMACEUTICALS | 3,055 | +0,16 % | Recursion Q1 2026 slides: AI pipeline advances amid revenue challenges | ||
| AIM IMMUNOTECH | 0,073 | -100,00 % | AIM ImmunoTech raises $4.2M through warrant exercise deal |
Das Unternehmen PROTAGENIC THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 1,588 Euro und damit -2,56 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PROTAGENIC THERAPEUTICS INC finden Sie auf Wallstreet Online.